Ibex Wealth Advisors boosted its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,995 shares of the medical research company’s stock after purchasing an additional 1,340 shares during the period. Amgen makes up approximately 1.0% of Ibex Wealth Advisors’ investment portfolio, making the stock its 27th biggest holding. Ibex Wealth Advisors’ holdings in Amgen were worth $13,908,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Quest 10 Wealth Builders Inc. increased its holdings in shares of Amgen by 220.0% in the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 55 shares during the period. Wellington Altus USA Inc. raised its position in shares of Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after acquiring an additional 34 shares in the last quarter. Nvwm LLC lifted its stake in shares of Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after purchasing an additional 66 shares during the last quarter. PFS Partners LLC lifted its stake in shares of Amgen by 95.5% during the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after purchasing an additional 42 shares during the last quarter. Finally, TOWER TRUST & INVESTMENT Co bought a new stake in shares of Amgen in the 3rd quarter valued at about $38,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Amgen News Roundup
Investors following AMGN have been watching these news items:
- Positive Sentiment: Argus raised its price target to $515 from $460 and maintained a buy rating, signaling further upside in its view. Article
- Neutral Sentiment: A Trefis article examines Amgen’s valuation relative to peers, but the provided summary does not include its conclusion. Article
- Negative Sentiment: One report puts the consensus price target at $422.76, below the recent reference price of $465.67; that gap could temper sentiment despite Argus’ more bullish forecast. Article
Amgen Stock Performance
Shares of NASDAQ AMGN traded down $1.39 during midday trading on Friday, reaching $465.67. The company had a trading volume of 2,122,101 shares, compared to its average volume of 2,720,013. Amgen Inc. has a 1 year low of $312.39 and a 1 year high of $483.99. The business’s 50-day simple moving average is $425.31 and its 200 day simple moving average is $381.17. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The stock has a market cap of $251.89 billion, a P/E ratio of 27.01, a P/E/G ratio of 3.25 and a beta of 0.43.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. During the same period in the previous year, the company earned $5.64 earnings per share. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, analysts forecast that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.
Amgen Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a yield of 2.2%. Amgen’s payout ratio is currently 58.47%.
Analyst Ratings Changes
AMGN has been the topic of a number of analyst reports. BMO Capital Markets cut their price objective on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a research report on Monday, October 12th. Truist Financial boosted their target price on Amgen from $380.00 to $398.00 and gave the stock a “hold” rating in a research note on Wednesday, November 4th. Piper Sandler upped their target price on Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Freedom Broker cut Amgen from a “buy” rating to a “hold” rating and increased their price target for the company from $450.00 to $470.00 in a research note on Friday, November 6th. Finally, Oppenheimer reissued an “outperform” rating on shares of Amgen in a report on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $424.66.
Get Our Latest Research Report on AMGN
Amgen Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
See Also
- Five stocks we like better than Amgen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
